NORD goes on record that IRA’s MDPNP will lead to stifling of innovation for rare disease community.With the Centers for Medicare and Medicaid Services (CMS) releasing its revised guidance1 detailing the requirements and parameters of the Inflation Reduction Act’s Medicare Drug Price Negotiation Program (MDPNP), NORD released its statement against the guidance.In the statement, it […]
